Modulating the effectiveness of mRNA therapies using modified ribonucleotides

Modulating the effectiveness of mRNA therapies using modified ribonucleotides

First Name

Last Name

Business Email Address

Job Title

Company Name

Address

Country

Mobile Phone

Postal Code

Are you or your group involved in mRNA in vitro transcription (IVT)

What are your main concerns regarding your IVT reaction?

Yield

dsRNA

Quality of raw materials (GMP / AOF)

Full length mRNA

Impurities from the raw materials

Capping of your mRNA

Other

In what stage of the mRNA production lifecycle are you working?

Process development

Analytical

Pre-clinical

Clinical trials

Commercial production

By checking this box, I am confirming that I would like to receive further communication from Roche. I can view Roche's Privacy Policy here.

Excessive mRNA immunogenicity can be prevented by incorporating modified ribonucleotides. 1, 2 Chemical modifications of mRNA are fairly common in nature and they influence post-transcriptional gene regulation in eukaryotes. Use of modified ribonucleotides in mRNA production contributes to immunogenicity reduction, as well as increased protein production.

Read on to learn more about modulating the effectiveness of mRNA therapies using modified ribonucleotides and more...